Biotech Values

[Mufaso]

Barron's just commented on Roche's CT-388 with analyst reactions. General analyst reactions:

• probably better than tirzepatide (Zepbound)
  
• not a lot of data provided by Roche in the presser
  
• cross trial comparisons are difficult and then they provided just top line comparison.

Roche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity By: Josh Nathan-Kazis, May 16, 2024, 10:08 am EDT

Roche (RHHBY) unveiled impressive early-stage results in a small trial of a weight-loss drug called CT-388...

...While comparisons between trials are difficult, and Roche provided only a bit of data in its press release, analysts said that the numbers might be better than those put up by the current king of the market, Eli Lilly LLY’s weight-loss drug Zepbound.

In a note on Thursday, William Blair analyst Andy Hsieh wrote that CT-388’s data looks strong when compared with earlier studies of Zepbound. “The rate and magnitude of weight loss exhibited by patients treated with CT-388 appears to be numerically better than those treated with Zepbound,” he wrote, adding various caveats about the lack of details and the difficulty of cross-trial comparisons.

Jefferies analyst Akash Tewari wrote in a separate note that CT-388’s efficacy results appeared “numerically higher” than those Eli Lilly’s weight loss drug Zepbound put up. He said they were in line with data on a promising experimental weight-loss drug from Viking Therapeutics VKTX

https://www.barrons.com/articles/roche-weight-loss-obesity-drug-eaa038c1